Please login to the form below

Not currently logged in
Email:
Password:

Europe pharma stocks take fall

European stocks have fallen today in the wake of drug test failures announced by Actelion and AstraZeneca

European stocks have fallen today in the wake of drug test failures announced by both Actelion and AstraZeneca.

Europe's largest biotech Actelion fell 8 per cent after its haemorrhage drug clazosentan failed in a late-stage study, lessening the chances of it making it to market.

AstraZeneca lost 1.5 per cent after the company's experimental prostate cancer pill zibotentan failed to improve survival in a late-stage clinical trial, dealing a fresh blow to its oncology pipeline.

"We've seen a bit of a pause for breath today and it seems like the market is running out of a bit of steam," said Joshua Raymond, markets strategist at City Index.

27th September 2010

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics